Evidence map›Paper›PMID 40264827›Full record

ArticlePathology oncology research : POR2025

Timely recognition of a probably life-threatening genodermatosis: familial case report of hereditary leiomyomatosis and renal cell cancer.

Judit Kárteszi, Nikoletta Nagy, Márta Széll, Zsuzsanna Lengyel, Dávid Semjén, Zsolt Egyházi, Gábor Bajzik, Levente Kuthi, Csaba Pusztai, Zita Battyáni

Abstract readCase Reports
In one paragraph

Article in Pathology oncology research : POR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Judit KártesziGenetic Counselling, Saint Raphael Hospital of Zala Castle County, Zalaegerszeg, Hungary.
Nikoletta NagyInstitute of Medical Genetics, University of Szeged, Szeged, Hungary.
Márta SzéllInstitute of Medical Genetics, University of Szeged, Szeged, Hungary.
Zsuzsanna LengyelDepartment of Dermatology, Venereology and Oncodermatology, University of Pécs, Pécs, Hungary.
Dávid SemjénDepartment of Pathology II. Histology and Cytology, University of Pécs, Pécs, Hungary.
Zsolt EgyháziDepartment of Pathology, Somogy County Moritz Kaposi Teaching Hospital, Kaposvár, Hungary.
Gábor BajzikDr. Baka József Diagnostic, Radiation Oncology, Research and Teaching Center, Somogy County Moritz Kaposi Teaching Hospital, Kaposvár, Hungary.
Levente KuthiDepartment of Surgical and Molecular Pathology, Tumor Pathology Center, National Institute of Oncology, Budapest, Hungary.
Csaba PusztaiDepartment of Urology, Somogy County Moritz Kaposi Teaching Hospital, Kaposvár, Hungary.
Zita BattyániDepartment of Dermatology, Venereology and Oncodermatology, University of Pécs, Pécs, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Autosomal dominant genodermatoses with a predisposition for cancer make up a well-described disease group with unique cutaneous alterations in each. This should urge dermatologists to think of other consequences beyond the skin. Histological examination serves as the gold standard, and it is an effective tool for the first investigation, even nowadays in the "next-generation genetic" era. Multiple appearances of benign tumours histologically proved to be cutaneous leiomyomatosis suggest a rare disorder with germline heterozygous pathogen variant in the Case presentation: Years before the easy accessibility of the complete genetic workup in Hungary, a yearly abdominal MRI check-up was suggested preventively for a middle-aged man with multiplex cutaneous leiomyomata. During the follow-up period papillary type 2 renal cell carcinoma was diagnosed in the left kidney at an early stage, and a successful operation saved his life without the need for aggressive chemotherapy or immunotherapy. Immunohistochemistry of tumour tissue proved FH-deficient renal cell cancer. We discuss in short the current knowledge of pathophysiology and accessible therapies regarding this aggressive malignant tumour type in the kidney, which is usually detected in the advanced stage with early metastasis. We also highlight an early sign, i.e., solitary cystic alteration in the kidney, which can be preliminarily observed before malignant transformation, which was also described in mouse models. Sanger sequencing and Multiplex-Ligation-Dependent Probe Amplification (MLPA) analysis of the Conclusion: Regular observation of individuals with hereditary leiomyomatosis may prevent a serious sequelae of untreatable renal malignancy.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsLeiomyomatosisNeoplastic Syndromes, HereditarySkin NeoplasmsUterine NeoplasmsFumarate HydrataseHumansMaleMiddle AgedPedigreeFumarate Hydrataseautosomal dominantcase reportfumarate hydratase deficiencyhereditary leiomyomatosisrenal cell cancer

Identifiers

PMID40264827
PMCPMC12011599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.